Bionure, a Spanish biotech company developing a first-in-class drug for the treatment of multiple sclerosis, is currently 115% overfunding on Capital Cell. With more than €1,100,246 raised, Bionure has broken the record for the highest amount raised on a Spanish life science equity crowdfunding platform.
Valued at 9,400,000€ and with an estimated ROI of 1400%, Bionure’s 258+ investors now share 9.27% equity in the biotech startup. The capital raised from will be used by the company to develop BN201, helping to aid about 2.5 million people worldwide and more than 600,000 in Europe who have M.S. To date there is no cure for the disease.
“Capital Cell has been a constant support helping to raise awareness of our campaign. The platform is a great way to expand funding possibilities, reaching investors that we would had never been able to reach,” praised Bionure CEO Albert G. Zamora.
Multiple sclerosis is a neurodegenerative disease in which the immune system destroys the nervous system by degrading the myelin layer that covers and protects the nerves. This new drug acts as a neuroprotector, preventing the nervous system from damage and reversing the detrimental effects. According to Bionure, at present, there is no other drug with this dual role of neuroprotection and regeneration, not only making BN201 both a unique product and hope to multiple sclerosis patients, but also other people suffering from neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
After more than six years of research, this late-preclinical drug development company based in Barcelona and California will now be able to take the next big and imperative step: to complete their preclinical phase and begin the BN201 promising phase-I clinical trials. They will test its effectiveness in patients with Acute Optic Neuritis (AON), a condition known to be one of the first signs of multiple sclerosis.
Bionure’s campaign ‘#estamosaesto’ (‘we are this close’) is capturing the interest of the crowd due to the significant social impact that BN201 has and the potential business opportunity that Bionure presents, considering that the estimated neuro regenerative drug market for a drug such as BN201 nears €1.2 billion.
“We have been contacted by multiple sclerosis patients, by their relatives and friends, who see this an exceptional opportunity to help,” commented Capital Cell CEO and Director Daniel Oliver, considering both points. “That’s why we are capturing the interest of big investors who see the high social impact but also the high profitability of their investment…This is a fantastic representation of Capital Cell as a reputable equity investment platform in the run up to our UK Launch.”
Following the success of Capital Cell in Spain, the company is currently in the pre-launch phase of expanding into the UK market.
“We’re showcasing some amazing, innovative scientific research projects, and giving smaller companies the opportunity to make big changes in the world of life science. Capital Cell provides investors at all levels with the opportunity to not only directly fund companies that can change lives, but also invest in one of the most profitable sectors around,” added Laura Ferguson, UK Director.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!